Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type 1. 1989

D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
Institute of Medical Chemistry and Biochemistry, University of Innsbruck, Austria.

Serum concentrations of interferon-gamma were measured in individuals seropositive for human immunodeficiency virus type 1 (HIV-1). According to the CDC classification system, 6 presented with stage IV-C, 5 with stage IV-A, 8 with stage III, and the remaining 24 individuals with stage II. A modified radioimmunoassay procedure for detection of interferon-gamma was used with a detection limit of 18 U/L. Approximately one-half (22/43) of the seropositives exhibited increased serum interferon-gamma concentrations compared with seronegative blood donors (n = 76). There was a significant association between serum interferon-gamma concentrations and CDC stages of the patients; patients classified as CDC IV-C had the highest concentrations. Further, a significant positive correlation was observed between serum interferon-gamma and serum neopterin concentrations in seropositive study participants. We conclude that interferon-gamma is present in increased concentrations in HIV-1 seropositives compared to seronegative blood donors. Diminished in vitro production of interferon-gamma by T-lymphocytes on stimulation with specific soluble antigens contrasts with increased levels of circulating interferon-gamma in patients.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001708 Biopterins Pterin derivatives based on 2-amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone. Biopterins are natural products that have been considered as growth factors for some insects. Biopterins are cofactors for the AROMATIC AMINO ACID hydroxylases and NITRIC OXIDE SYNTHASE. Deficiencies in BIOPTERINS metabolism (e.g., lowered TETRAHYDROBIOPTERIN) are associated with neurological deterioration (e.g., HYPERPHENYLALANINAEMIA). 2-Amino-6-((1S,2R)-1,2-dihydroxypropyl)-4(1H)-pteridinone,2-Amino-6-((1S,2S)-1,2-dihydroxypropyl)-4(1H)-pteridinone,2-Amino-6-(1,2-dihydroxypropyl)-4(8H)-pteridinone,2-amino-6-((1R,2R)-1,2-dihydroxypropyl)-4(3H)-pteridinone,4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-, (S-(R*,S*))-,6-Biopterin,Biopterin,D-threo-Biopterin,L-Biopterin,L-erythro-Biopterin,L-threo-Biopterin,2-Amino-6-(1,2-dihydroxypropyl)-4(1H)-pteridinone,Dictyopterin,Orinapterin,6 Biopterin,D threo Biopterin,L Biopterin,L erythro Biopterin,L threo Biopterin
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D019798 Neopterin A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of BIOPTERINS. 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone,Monapterin,Neopterin, (R*, R*)-Isomer,Neopterin, (erythro-D)-Isomer,Neopterin, (erythro-L)-Isomer,Neopterin, (threo-D)-Isomer,Neopterin, (threo-L)-Isomer,Umanopterin

Related Publications

D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
January 2009, Journal of virology,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
December 1990, Journal of clinical microbiology,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
January 1992, Journal of acquired immune deficiency syndromes,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
April 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
August 1999, The Journal of infectious diseases,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
January 1990, Disease markers,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
May 1989, Proceedings of the National Academy of Sciences of the United States of America,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
June 1991, Clinical immunology and immunopathology,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
June 1991, Immunology letters,
D Fuchs, and A Hausen, and G Reibnegger, and E R Werner, and G Werner-Felmayer, and M P Dierich, and H Wachter
September 1993, AIDS research and human retroviruses,
Copied contents to your clipboard!